First patient undergoes Luxturna gene therapy on NHS by Anna Smith | Feb 18, 2020 | News | 0 Jake Ternet, patient at Moorfields Eye Hospital was the first in the UK to receive the treatment. Read More
EU OKs Novartis’ gene therapy Luxturna for rare retinal disease by Selina McKee | Nov 25, 2018 | News | 0 Novartis’ Luxturna has been approved by regulators in Europe to treat a rare inherited condition that causes sight loss. Read More
Novartis buys access to Spark’s vision loss therapy by Selina McKee | Jan 25, 2018 | News | 0 Novartis has bought itself rights to Spark Therapeutic’s gene therapy for a certain type of vision loss, in a deal worth up to $170 million. Read More